On Friday, the Massachusetts-based biotech said the FDA informed Blueprint two days ago that it is placing a partial hold on a Phase I/II study, also known as the VELA trial, looking at BLU-222 in advanced solid tumors. The partial hold was due to adverse effects being observed in a “limited number” of patients, Blueprint said.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,